Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1
|
作者：
Waks, A. G. [1 ]
Gharaibeh, M. [2 ]
Sjekloca, N. [3 ]
Poluparthi, N. [2 ]
Shah, A. [2 ]
Bergamaco, E. [4 ]
MacCannell, T. [2 ]
Leung, G. [5 ]
Ntalla, I. [6 ]
Oko-osi, H. [2 ]
Tolaney, S. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA
[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA
[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA
[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA
[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253P
引用
收藏
页码：S653 / S653
页数：1
相关论文
共 50 条
  • [21] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [22] PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
    Martinez-Janez, Noelia
    Ezquerra, Meritxell Bellet
    Henao, Fernando
    Manso, Luis
    Anton, Antonio
    Zamora, Pilar
    Murillo, Serafin Morales
    Tolosa, Pablo
    Andres, Raquel
    Calvo, Lourdes
    Galve, Elena
    Lopez, Rafael
    de la Pena, Francisco Ayala
    Lopez-Tarruella, Sara
    Boronat, Laia
    Martos, Tamara
    Chacon, J. Ignacio
    Alvarez, Isabel
    de la Haba-Rodriguez, Juan
    Anton, Fernando Moreno
    CANCER RESEARCH, 2023, 83 (05)
  • [23] TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2-breast cancer
    Bardia, Aditya
    Jhaveri, Komal
    Kalinsky, Kevin
    Pernas, Sonia
    Tsurutani, Junji
    Xu, Binghe
    Hamilton, Erika
    Im, Seock-Ah
    Nowecki, Zbigniew
    Sohn, Joohyuk
    De Laurentiis, Michelino
    Martinez Janez, Noelia
    Adamo, Barbara
    Lee, Keun Seok
    Jung, Kyung Hae
    Rubovszky, Gabor
    Tseng, Ling-Ming
    Lu, Yen-Shen
    Yuan, Yuan
    Maxwell, Micah J.
    Haddad, Vincent
    Khan, Sabrina S.
    Rugo, Hope S.
    Pistilli, Barbara
    FUTURE ONCOLOGY, 2024, 20 (08) : 423 - 436
  • [24] Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)
    Avesani, Barbara
    Giontella, Elena
    Caldart, Alberto
    De Noni, Alessandro
    Muzzarelli, Alice
    Borghesani, Giulia
    Insolda, Jessica
    Biondani, Pamela
    Parolin, Veronica
    Pellini, Francesca
    Scarpa, Aldo
    Nottegar, Alessia
    Lawlor, Rita T.
    Mafficini, Andrea
    Paris, Ida
    Minucci, Angelo
    Pasciuto, Tina
    Fabi, Alessandra
    Fiorio, Elena
    Milella, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [27] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [28] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [29] Observational study of HR+/HER2-metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)
    Blanch, Salvador
    Gil-Gil, Juan Miguel
    Arumi, Miriam
    Aguirre, Elena
    Segui, Miguel Angel
    Atienza, Manuel
    Diaz-Cerezo, Silvia
    Molero, Alberto
    Cervera, Jose Manuel
    Gavila, Joaquin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2950 - 2959
  • [30] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
    Hamilton, E. P.
    Cortes, J.
    Ozyilkan, O.
    Chen, S-C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Huober, J.
    Chapman, S. C.
    Yang, Z.
    Chen, Y.
    Johnston, E. L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
12345